TY - JOUR
TI - Salt intake in mineralocorticoid receptor antagonist-treated primary aldosteronism: foe or ally?
AU - Fountoulakis, S.
AU - Papanastasiou, L.
AU - Voulgaris, N.
AU - Kounadi, T.
AU - Markou, A.
AU - Chrousos, G.P.
AU - Piaditis, G.
JO - Vitamins and Hormones
PY - 2020
VL - 19
TODO - 2
SP - 223-232
PB - Springer-Verlag
SN - null
TODO - 10.1007/s42000-019-00167-9
TODO - aldosterone;  calcium channel blocking agent;  eplerenone;  mineralocorticoid antagonist;  potassium;  sodium;  spironolactone;  mineralocorticoid antagonist;  potassium;  sodium, adult;  aged;  aldosterone blood level;  Article;  blood pressure monitoring;  blood pressure regulation;  body mass;  clinical article;  controlled study;  diastolic blood pressure;  disease severity;  female;  human;  hyperkalemia;  hypertension;  kaliuresis;  male;  plasma renin activity;  potassium blood level;  potassium urine level;  primary hyperaldosteronism;  prospective study;  salt intake;  sodium blood level;  sodium restriction;  sodium urine level;  systolic blood pressure;  treatment duration;  administration and dosage;  blood;  blood pressure;  follow up;  hyperaldosteronism;  hyperkalemia;  middle aged;  pathophysiology;  salt intake;  urine, Aged;  Blood Pressure;  Female;  Follow-Up Studies;  Humans;  Hyperaldosteronism;  Hyperkalemia;  Male;  Middle Aged;  Mineralocorticoid Receptor Antagonists;  Potassium;  Sodium;  Sodium Chloride, Dietary
TODO - Mild hyperkalemia is a common side effect of mineralocorticoid receptor antagonist (MRA) treatment of patients with primary aldosteronism (PA), which can be worsened by instructions to minimize salt intake. Our objective was to evaluate the effect of salt consumption on serum potassium levels and mean, mean minimal, and mean maximal systolic and diastolic blood pressure (BP) in MRA-treated hyperkalemic PA patients under relative salt restriction. Seventeen consecutive mildly hyperkalemic MRA-treated PA patients aged 66.3 ± 8.37 years were recruited. Body mass index (BMI) and BP were assessed, and serum and 24-h urinary sodium and potassium levels, plasma renin, and serum aldosterone were measured, while patients followed a relatively salt-restricted diet, after 1 month of controlled salt supplementation (usual salt-restricted diet plus 4 g salt/day) and after 6 months on instructions for free dietary salt consumption. Baseline salt consumption was additionally evaluated in two more patient groups (normotensive subjects and normokalemic MRA-treated PA patients). One month of controlled salt supplementation (24-h urine sodium (median, min, max): 195.2 (120.30–275.20) vs 110.13 (34.30–139.20) mEq/day, p < 0.001) resulted in increased kaliuresis (62.25 (40.69–97.0) vs 54.0 (23.28–79.60) mEq/day, p = 0.001) and a decrease of serum potassium (5.2 (5–5.70) vs 4.6 (3.8–5.1) mEq/L, p < 0.001), while serum sodium (139 (133–141) vs 1 39 (135–144) mEq/L) and mean systolic (130 (105–141 vs. 130 (106–141) mmHg) and diastolic (76 (53–85) vs75 (53–84) mmHg) BP remained stable. These findings were unchanged after 6 months of free salt consumption. BMI remained constant, while plasma renin and serum aldosterone decreased following salt repletion. Adequate salt consumption attenuates MRA-induced hyperkalemia in relatively salt-restricted PA patients without affecting BP or BMI. © 2019, Hellenic Endocrine Society.
ER -